About the department
The Department of Clinical Oncology
The Department of Clinical Oncology is an academic department specializing in a full spectrum of non-surgical cancer services, including radiotherapy, chemotherapy, biological targeted therapy and palliative care. The Department provides state-of-the-art cancer management at two hospitals in close collaboration with multiple disciplines. The Queen Mary Hospital in Hong Kong was a University teaching hospital founded in 1937. The University of Hong Kong-Shenzhen Hospital in China, opened in 2012, was an affiliated hospital with the mission of providing the best evidence-based treatment in accordance with international standards, training healthcare workers and stimulating health reforms in China.
In 2022, the Department of Clinical Oncology became a founding member of the Centre of Cancer Medicine, a platform to facilitate the academic development of oncology, created to foster collaboration among cognate disciplines and (sub)specialties within the Centre of Cancer Medicine under the School of Clinical Medicine, and with other Schools, Departments, Institutes, Hospitals and Colleges.
Both hospitals are well-equipped with comprehensive range of modern technologies including 4D simulation, computerized planning, intensity-modulated/ volumetric arc radiotherapy with image guidance and respiratory control, stereotactic radiosurgery or radiotherapy, and high-dose-rate remote after-loading brachytherapy. Both hospitals are also well-equipped with facilities for safe preparation and administration of chemotherapy.
The Department at Queen Mary Hospital (Hong Kong), in collaboration with the Hospital Authority Department of Clinical Oncology, sees over 2600 new cancer patients per year. The Department at University of Hong Kong-Shenzhen Hospital (China), one of the designated Centres of Excellence, has been developing rapidly since service commencement in 2013, the projected number of new cases will exceed 2200 in 2015. Besides globally common cancer (e.g., lung, colorectal and breast cancers), Asian prevalent cancers (e.g. nasopharyngeal carcinoma, liver, esophagus and gastric cancers) are often treated.